Post-approval studies (Phase 4)Study completedNCT02177071
What this trial is testing
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Who this might be right for
Crohn's Disease
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives 211